What is Leerink Partnrs' Estimate for ABT FY2025 Earnings?

Abbott Laboratories (NYSE:ABT - Free Report) - Equities research analysts at Leerink Partnrs issued their FY2025 earnings per share (EPS) estimates for shares of Abbott Laboratories in a research report issued on Monday, June 16th. Leerink Partnrs analyst M. Kratky forecasts that the healthcare product maker will post earnings per share of $5.15 for the year. Leerink Partnrs has a "Hold" rating on the stock. The consensus estimate for Abbott Laboratories' current full-year earnings is $5.14 per share.

Other research analysts have also issued research reports about the company. Jefferies Financial Group boosted their price target on Abbott Laboratories from $135.00 to $137.00 and gave the stock a "hold" rating in a research report on Thursday, April 17th. Stifel Nicolaus lifted their target price on Abbott Laboratories from $135.00 to $145.00 and gave the stock a "buy" rating in a research note on Thursday, April 17th. Bank of America lifted their target price on Abbott Laboratories from $133.00 to $150.00 and gave the stock a "buy" rating in a research note on Monday, March 10th. Wells Fargo & Company lifted their target price on Abbott Laboratories from $136.00 to $147.00 and gave the stock an "overweight" rating in a research note on Thursday, April 17th. Finally, The Goldman Sachs Group lifted their target price on Abbott Laboratories from $138.00 to $154.00 and gave the stock a "buy" rating in a research note on Tuesday, March 4th. Six equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and a consensus target price of $142.61.

Abbott Laboratories Stock Down 1.4%

NYSE:ABT opened at $132.18 on Wednesday. The firm has a market capitalization of $229.97 billion, a price-to-earnings ratio of 17.14, a price-to-earnings-growth ratio of 2.53 and a beta of 0.73. Abbott Laboratories has a twelve month low of $99.71 and a twelve month high of $141.23. The stock's 50 day moving average price is $131.80 and its two-hundred day moving average price is $126.62. The company has a quick ratio of 1.27, a current ratio of 1.78 and a debt-to-equity ratio of 0.26.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.02. The firm had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.38 billion. Abbott Laboratories had a return on equity of 19.01% and a net margin of 31.89%.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th will be given a dividend of $0.59 per share. The ex-dividend date is Tuesday, July 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.79%. Abbott Laboratories's payout ratio is 30.61%.

Insider Activity

In other news, Director Sally E. Blount sold 2,600 shares of the company's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total transaction of $337,116.00. Following the completion of the sale, the director now directly owns 34,058 shares in the company, valued at approximately $4,415,960.28. This represents a 7.09% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.46% of the company's stock.

Institutional Trading of Abbott Laboratories

A number of institutional investors have recently modified their holdings of ABT. Redwood Park Advisors LLC bought a new stake in shares of Abbott Laboratories during the 4th quarter valued at $25,000. Noble Wealth Management PBC acquired a new position in shares of Abbott Laboratories during the 4th quarter worth $26,000. NewSquare Capital LLC raised its holdings in shares of Abbott Laboratories by 78.4% during the 4th quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker's stock worth $27,000 after buying an additional 105 shares in the last quarter. Hughes Financial Services LLC acquired a new position in shares of Abbott Laboratories during the 1st quarter worth $27,000. Finally, WealthTrak Capital Management LLC acquired a new position in shares of Abbott Laboratories during the 4th quarter worth $28,000. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.